Investors & Media

Stock Info
NASDAQBCLI
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

Brainstorm’s Alzheimer’s Key Opinion Leader Event

Brainstorm’s July 8, 2020 Key Opinion Leader (KOL) Webinar on the Company's Alzheimer's Disease (AD) Clinical Program.

Corresponding Presentation

Recent News
Dec 7, 2021

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, and Catalent (NYSE: CTLT), a global leader in enabling biopharma, cell,...

Dec 2, 2021

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that biomarker data on NurOwn® will be presented at the...

Nov 29, 2021

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the Phase 3 trial...

View All

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds